Medical Devices

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.

A global consortium pioneers new drugs designed specifically for children, moving away from harsh adult treatments for aggressive pediatric cancers.

ViruSure's new GMP-validated test using Oxford Nanopore sequencing promises to slash drug safety testing times, boosting supply chain resilience.

A new study reveals Canadians lost billions in wages waiting for care. This is the staggering personal and economic cost of the nation's healthcare queues.

K-pop sensation Kim Sejeong is the new face of REJURAN, a move merging celebrity appeal with advanced skin science to expand K-beauty's global reach.

A new report projects the telehealth market will skyrocket to over $2 trillion by 2034, signaling a seismic shift in how we receive medical care.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

Relmada Therapeutics stock skyrockets on promising bladder cancer data and a $160M financing deal, setting a high-stakes stage for its investor conference.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

A startup using trained dogs and AI to sniff out cancer from breath samples was just named a "Fierce 15" company. Can this technology change screening?

GE HealthCare's new FDA-cleared 'View' viewer promises to free radiologists from the workstation with a cloud-native, zero-footprint solution.

A novel stent designed specifically for the brain's veins shows immediate success in its first human tests, offering new hope for a debilitating condition.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

As electroCore preps its 2025 financial report, all eyes are on its product growth, the new Quell device, and its path to profitability in the booming bioelectronic market.

Medicus Pharma's microneedle patch for basal cell carcinoma clears nearly three-quarters of lesions, offering a potential non-surgical alternative to the scalpel.

A new surgical robot from Beijing's Healinno Tech uses AI and a high-pressure waterjet to treat prostate issues with unprecedented precision and safety.

With new data on CUE-401, a novel therapy inspired by Nobel-winning science, Cue Biopharma makes a high-stakes play to redefine autoimmune treatment.

Despite lower annual revenue, 3D Systems reports a full-year profit driven by a major divestiture and strong growth in healthcare and aerospace sectors.

A year after rebranding from FibroGen, Kyntra Bio's first full-year report will test if its lean strategy can fuel its ambitious oncology pipeline.

A new non-thermal ablation technology shows long-term success in shrinking thyroid nodules with high patient satisfaction, potentially disrupting surgical norms.